Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 101 Published: March 31, 2021 Report Code: GMDGDHC12783IDB

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy – Drugs in Development, 2021, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape.

Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, drowsiness or confusion, change in sleep patterns, slurred speech and agitation, excitement, or seizures (occur rarely). The predisposing factors include gastrointestinal bleeding, increased protein intake, renal dysfunction with azotemia, constipation (due to increased nitrogen load), drugs (particularly sedatives and diuretics) and hypoxia.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Hepatic Encephalopathy – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatic Encephalopathy (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 6, 4 and 4 respectively.

Hepatic Encephalopathy (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy (Gastrointestinal).

– The pipeline guide reviews pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Hepatic Encephalopathy (Gastrointestinal) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Hepatic Encephalopathy (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Hepatic Encephalopathy (Gastrointestinal).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Hepatic Encephalopathy (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

Alfasigma SpA
Axcella Health Inc
Cosmo Pharmaceuticals NV
Grifols SA
Kaleido Biosciences Inc
Mallinckrodt Plc
Neuropathix Inc
Rebiotix Inc
Takeda Pharmaceutical Co Ltd
TenNor Therapeutics Ltd
Umecrine Cognition AB
Versantis AG

Table of Contents

Table of Contents

Introduction

Hepatic Encephalopathy – Overview

Hepatic Encephalopathy – Therapeutics Development

Hepatic Encephalopathy – Therapeutics Assessment

Hepatic Encephalopathy – Companies Involved in Therapeutics Development

Hepatic Encephalopathy – Drug Profiles

Hepatic Encephalopathy – Dormant Projects

Hepatic Encephalopathy – Discontinued Products

Hepatic Encephalopathy – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Hepatic Encephalopathy, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Hepatic Encephalopathy – Pipeline by Alfasigma SpA, 2021

Hepatic Encephalopathy – Pipeline by Axcella Health Inc, 2021

Hepatic Encephalopathy – Pipeline by Cosmo Pharmaceuticals NV, 2021

Hepatic Encephalopathy – Pipeline by Grifols SA, 2021

Hepatic Encephalopathy – Pipeline by Kaleido Biosciences Inc, 2021

Hepatic Encephalopathy – Pipeline by Mallinckrodt Plc, 2021

Hepatic Encephalopathy – Pipeline by Neuropathix Inc, 2021

Hepatic Encephalopathy – Pipeline by Rebiotix Inc, 2021

Hepatic Encephalopathy – Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Hepatic Encephalopathy – Pipeline by TenNor Therapeutics Ltd, 2021

Hepatic Encephalopathy – Pipeline by Umecrine Cognition AB, 2021

Hepatic Encephalopathy – Pipeline by Versantis AG, 2021

Hepatic Encephalopathy – Dormant Projects, 2021

Hepatic Encephalopathy – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Hepatic Encephalopathy, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Pharmaceuticals
New
Heart Failure Epidemiology Analysis and Forecast to 2032
$3,995 | September 2023
Pharmaceuticals
New
Genomics in pharma: genetic engineered T-cells
$250 | September 2023